Oncotarget

Research Papers:

No association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects

Anqi Zhang, Ting-Yan Shi, Yuan Zhao, Junmiao Xiang, Danyang Yu, Zongwen Liang, Chaoyi Xu, Qiong Zhang, Yue Hu, Danhan Wang, Jing He and Ping Duan _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:112761-112769. https://doi.org/10.18632/oncotarget.22603

Metrics: PDF 264 views  |   HTML 692 views  |   ?  


Abstract

Anqi Zhang1,*, Ting-Yan Shi2,*, Yuan Zhao1, Junmiao Xiang1, Danyang Yu1, Zongwen Liang1, Chaoyi Xu1, Qiong Zhang1, Yue Hu1, Danhan Wang1, Jing He1,3 and Ping Duan1

1Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China

2Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

3Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China

*These authors have contributed equally to this work

Correspondence to:

Ping Duan, email: dppddpp@126.com

Jing He, email: hejing198374@gmail.com

Keywords: TP53; polymorphism; ovarian cancer; susceptibility; meta-analysis

Received: June 10, 2017     Accepted: November 04, 2017     Published: November 21, 2017

ABSTRACT

The TP53 gene product is an important regulator of cell growth and a tumor suppressor. The association between TP53 Arg72Pro polymorphism and ovarian cancer risk has been widely investigated, but the results are contradictory. We therefore searched the PubMed, EMBASE and Chinese Biomedical databases for studies on the relation between TP53 Arg72Pro polymorphism and ovarian cancer risk. Our final meta-analysis included 24 published studies with 3271 cases and 6842 controls. Pooled results indicated that there was no significant association between TP53 Arg72Pro polymorphism and ovarian cancer risk [Pro/Pro vs. Arg/Arg: odds ratio (OR) =1.04, 95% confidence interval (CI) = 0.81-1.34; Arg/Pro vs. Arg/Arg: OR = 1.14, 95% CI = 0.96-1.36; recessive: OR = 1.05, 95% CI = 0.90-1.22; dominant: OR = 1.12, 95% CI = 0.94-1.33; and Pro vs. Arg: OR = 1.06, 95% CI=0.93-1.20]. Likewise, stratified analyses failed to reveal a genetic association. Despite some limitations, the present meta-analysis provides statistical evidence indicating a lack of association between TP53 Arg72Pro polymorphism and ovarian cancer risk.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22603